Literature DB >> 30150298

The C9ORF72 Gene, Implicated in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Encodes a Protein That Functions in Control of Endothelin and Glutamate Signaling.

Vitalay Fomin1, Patricia Richard1, Mainul Hoque2, Cynthia Li1, Zhuoying Gu1, Mercedes Fissore-O'Leary1, Bin Tian2, Carol Prives1, James L Manley3.   

Abstract

A GGGGCC repeat expansion in the C9ORF72 (C9) gene is the most common known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Several mechanisms have been proposed to account for its toxicity, including the possibility that reduced C9 protein levels contribute to disease. To investigate this possibility, we examined the effects of reduced C9 levels in several cell systems. We first showed that C9 knockdown (KD) in U87 glioblastoma cells results in striking morphological changes, including vacuolization and alterations in cell size. Unexpectedly, RNA analysis revealed changes in expression of many genes, including genes involved in endothelin (EDN) signaling and immune system pathways and multiple glutamate cycling genes (e.g., EAAT2), which were verified in several cell models, including astrocytes and brain samples from C9-positive patients. Consistent with deregulation of the glutamate cycling genes, elevated intracellular glutamate was detected in both KD cells and patient astrocytes. Importantly, levels of mRNAs encoding EDN1 and its receptors, known to be elevated in ALS, were sharply increased by C9 KD, likely resulting from an observed activation of NF-κB signaling and/or a possible role of a C9 isoform in gene control.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  NF-κB signaling; amyotrophic lateral sclerosis; endothelin; glutamate; glutamine; transcription

Mesh:

Substances:

Year:  2018        PMID: 30150298      PMCID: PMC6206455          DOI: 10.1128/MCB.00155-18

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  106 in total

Review 1.  Riluzole: what it does to spinal and brainstem neurons and how it does it.

Authors:  Alessandra Cifra; Graciela L Mazzone; Andrea Nistri
Journal:  Neuroscientist       Date:  2012-05-16       Impact factor: 7.519

2.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Authors:  Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

3.  Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis.

Authors:  Shangxi Xiao; Laura MacNair; Philip McGoldrick; Paul M McKeever; Jesse R McLean; Ming Zhang; Julia Keith; Lorne Zinman; Ekaterina Rogaeva; Janice Robertson
Journal:  Ann Neurol       Date:  2015-08-29       Impact factor: 10.422

4.  Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis.

Authors:  D Schiffer; S Cordera; P Cavalla; A Migheli
Journal:  J Neurol Sci       Date:  1996-08       Impact factor: 3.181

Review 5.  Glia as drivers of abnormal neuronal activity.

Authors:  Stefanie Robel; Harald Sontheimer
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

6.  C9orf72 is required for proper macrophage and microglial function in mice.

Authors:  J G O'Rourke; L Bogdanik; A Yáñez; D Lall; A J Wolf; A K M G Muhammad; R Ho; S Carmona; J P Vit; J Zarrow; K J Kim; S Bell; M B Harms; T M Miller; C A Dangler; D M Underhill; H S Goodridge; C M Lutz; R H Baloh
Journal:  Science       Date:  2016-03-18       Impact factor: 47.728

Review 7.  SQSTM1 mutations--bridging Paget disease of bone and ALS/FTLD.

Authors:  Sarah L Rea; Veronika Majcher; Mark S Searle; Rob Layfield
Journal:  Exp Cell Res       Date:  2014-01-30       Impact factor: 3.905

8.  Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS.

Authors:  Helene Tran; Sandra Almeida; Jill Moore; Tania F Gendron; UmaDevi Chalasani; Yubing Lu; Xing Du; Jeffrey A Nickerson; Leonard Petrucelli; Zhiping Weng; Fen-Biao Gao
Journal:  Neuron       Date:  2015-09-23       Impact factor: 17.173

Review 9.  C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jonathan D Rohrer; Adrian M Isaacs; Sarah Mizielinska; Simon Mead; Tammaryn Lashley; Selina Wray; Katie Sidle; Pietro Fratta; Richard W Orrell; John Hardy; Janice Holton; Tamas Revesz; Martin N Rossor; Jason D Warren
Journal:  Lancet Neurol       Date:  2015-01-29       Impact factor: 44.182

10.  c-Jun, JNK/SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis.

Authors:  A Migheli; R Piva; C Atzori; D Troost; D Schiffer
Journal:  J Neuropathol Exp Neurol       Date:  1997-12       Impact factor: 3.685

View more
  15 in total

Review 1.  Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update.

Authors:  Rocio Garcia-Santibanez; Matthew Burford; Robert C Bucelli
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-17       Impact factor: 5.081

Review 2.  Astrocytes in Neurodegeneration: Inspiration From Genetics.

Authors:  Jingxuan Huang; Chunyu Li; Huifang Shang
Journal:  Front Neurosci       Date:  2022-06-24       Impact factor: 5.152

Review 3.  From Pinocytosis to Methuosis-Fluid Consumption as a Risk Factor for Cell Death.

Authors:  Markus Ritter; Nikolaus Bresgen; Hubert H Kerschbaum
Journal:  Front Cell Dev Biol       Date:  2021-06-23

Review 4.  Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers.

Authors:  Björn F Vahsen; Elizabeth Gray; Alexander G Thompson; Olaf Ansorge; Daniel C Anthony; Sally A Cowley; Kevin Talbot; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2021-04-29       Impact factor: 42.937

Review 5.  Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment.

Authors:  Tereza Filipi; Zuzana Hermanova; Jana Tureckova; Ondrej Vanatko; And Miroslava Anderova
Journal:  J Clin Med       Date:  2020-01-18       Impact factor: 4.241

Review 6.  Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach.

Authors:  Shareen Singh; Thakur Gurjeet Singh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 7.  The Links between ALS and NF-κB.

Authors:  Emma Källstig; Brian D McCabe; Bernard L Schneider
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 8.  Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Authors:  Mehdi Ghasemi; Kiandokht Keyhanian; Catherine Douthwright
Journal:  Cells       Date:  2021-01-28       Impact factor: 6.600

9.  C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation.

Authors:  Deepti Lall; Ileana Lorenzini; Thomas A Mota; Shaughn Bell; Thomas E Mahan; Jason D Ulrich; Hayk Davtyan; Jessica E Rexach; A K M Ghulam Muhammad; Oksana Shelest; Jesse Landeros; Michael Vazquez; Junwon Kim; Layla Ghaffari; Jacqueline Gire O'Rourke; Daniel H Geschwind; Mathew Blurton-Jones; David M Holtzman; Rita Sattler; Robert H Baloh
Journal:  Neuron       Date:  2021-06-15       Impact factor: 18.688

Review 10.  C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD?

Authors:  Elke Braems; Bart Swinnen; Ludo Van Den Bosch
Journal:  Acta Neuropathol       Date:  2020-09-02       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.